Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

Status:
NOT_YET_RECRUITING

Trial end date:
2027-07-19

Target enrollment:

Participant gender:

Summary

The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.

Phase:

PHASE1

Details

Lead Sponsor:

Novartis Pharmaceuticals